Tuesday, June 2, 2015. Findings from a clinical trial reported online on May 20, 2015 in the American Journal of Clinical Nutrition reveal improvements in muscle mass and function in adults supplemented with omega 3 polyunsaturated fatty acids (PUFA) in comparison with a placebo group.
"Results from studies conducted in cancer patients, people with rheumatoid arthritis, and resistance-exercise–trained people suggested that fish oil–derived omega 3 PUFAs can stimulate muscle growth and enhance strength," Gordon I. Smith and colleagues note in their introduction to the article. "However, to our knowledge, a robust assessment of their effects on muscle mass and function in the older adult population has not been made."
Researchers at Missouri's Washington University School of Medicine randomized 60 men and women between the ages of 60 and 85 years to receive supplements containing a total of 1.86 grams eicosapentaenoic acid (EPA) and 1.5 grams docosahexaenoic acid (DHA), or a placebo daily for six months. In addition to blood omega 3 levels and other factors, thigh muscle volume, handgrip strength, one-repetition maximum upper and lower body strength, and average isokinetic muscle power were evaluated at the beginning of the study, at three months (with the exception of thigh muscle volume) and at the end of the treatment period.
After six months, red blood cell omega 3 levels had increased by 135% among those who received the fatty acids while remaining unchanged in the placebo group. Thigh muscle volume, handgrip strength and one-repetition maximum muscle strength were significantly increased in omega 3 fatty acid supplemented participants in comparison with the control group at six months. Average isokinetic muscle power also showed a tendency toward improvement after six months in the omega 3 group.
"Results from our study show that fish oil–derived omega 3 PUFA therapy has clinically important muscle anabolic and physical performance–enhancing effects in older adults," the authors conclude. "Additional studies are needed to determine whether long-term omega 3 PUFA therapy can sufficiently slow the declines in muscle mass and function that normally occur in older adults to significantly delay or even prevent sarcopenia and a loss of physical independence or cure it in already sarcopenic persons."
|